<DOC>
	<DOC>NCT02801565</DOC>
	<brief_summary>Observe validity of Recombinant Human Growth Hormone Injection assisted in IVF-ET (in vitro fertilization and embryo transfer) treatment of PCOS (polycystic ovary syndrome) patients.</brief_summary>
	<brief_title>Clinical Observation of Recombinant Human Growth Hormone Injection Assisted IVF-ET in the Treatment of PCOS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Age between 25 and 35 years old, married female and infertile. BMI≥25kg/m2. Diagnosed as PCOS. No obvious chronic organic diseases, such as liver, kidney, heart, lung, thyroid, adrenal disease. Subjects do not take part in other clinical trial study within 3 months. The subjects sign the informed consent form. BMI＜25kg/m2. Hyperprolactinemia and congenital adrenal cortical hyperplasia. Diabetes, thyroid function hyperthyroidism, thyroid dysfunction, cushing's syndrome. Pelvic and peritoneal tumor and tumor secreting hyperandrogenism. Severe acute and chronic liver and kidney disease, such as liver cirrhosis, acute and chronic renal failure, hepatitis B virus activity. Liver and kidney dysfunction, AST/ALT is 2.5 times higher than the normal limit, the serum of creatinine is 2 times higher than the normal level. Diseases affecting outcome of IVF pregnancy, eg, hydrosalpinx, hysteromyoma＞4 cm, adenomyosis, endometriosis, endometrial cyst of ovary, unilateral ovary, tuberculosis of reproductive system. Allergic to E. coli. expression product and its excipients. Being involved in other drug clinical researchers. The researchers consider who is not suitable for the group.</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>